Literature DB >> 28247267

Options for Treating Pain in Cancer Patients with Dysphagia.

Sebastiano Mercadante1.   

Abstract

Patients with chronic pain often develop dysphagia during the course of an advanced disease such as cancer. Opioids are the cornerstone of the management of cancer pain and are commonly administered orally. However, the oral route does not suit patients with dysphagia, who require alternative methods to administer analgesic drugs. Opioids given by parenteral or transdermal routes provide adequate pain control, being at least as efficacious as the oral route, but knowledge and experience in conversion ratios are mandatory when using these routes of administration. For breakthrough pain, transmucosal fentanyl preparations should be the preferred option and these can be given as needed due to the route of absorption. In addition, a new class of opioid formulations has been developed for use in dysphagic patients that are administered via nasogastric or enteral tubes while maintaining their sustained-release properties.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28247267     DOI: 10.1007/s40265-017-0710-8

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  37 in total

Review 1.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

Authors:  Augusto Caraceni; Geoffrey Hanks; Stein Kaasa; Michael I Bennett; Cinzia Brunelli; Nathan Cherny; Ola Dale; Franco De Conno; Marie Fallon; Magdi Hanna; Dagny Faksvåg Haugen; Gitte Juhl; Samuel King; Pål Klepstad; Eivor A Laugsand; Marco Maltoni; Sebastiano Mercadante; Maria Nabal; Alessandra Pigni; Lukas Radbruch; Colette Reid; Per Sjogren; Patrick C Stone; Davide Tassinari; Giovambattista Zeppetella
Journal:  Lancet Oncol       Date:  2012-02       Impact factor: 41.316

Review 2.  Intravenous morphine for management of cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Lancet Oncol       Date:  2010-05       Impact factor: 41.316

3.  Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients.

Authors:  Sebastiano Mercadante; Federica Aielli; Claudio Adile; Patrizia Ferrera; Alessandro Valle; Flavio Fusco; Amanda Caruselli; Claudio Cartoni; Pizzuto Massimo; Francesco Masedu; Marco Valenti; Giampiero Porzio
Journal:  Support Care Cancer       Date:  2015-04-03       Impact factor: 3.603

Review 4.  Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project.

Authors:  Lukas Radbruch; Peter Trottenberg; Frank Elsner; Stein Kaasa; Augusto Caraceni
Journal:  Palliat Med       Date:  2011-07       Impact factor: 4.762

5.  Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.

Authors:  Angela Maria Sousa; José de Santana Neto; Gabriel M N Guimaraes; Giovana M Cascudo; José Osvaldo B Neto; Hazem A Ashmawi
Journal:  Support Care Cancer       Date:  2013-11-21       Impact factor: 3.603

Review 6.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 7.  Opioids and renal function.

Authors:  Sebastiano Mercadante; Edoardo Arcuri
Journal:  J Pain       Date:  2004-02       Impact factor: 5.820

Review 8.  Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.

Authors:  Davide Tassinari; Sergio Sartori; Emiliano Tamburini; Emanuela Scarpi; William Raffaeli; Paola Tombesi; Marco Maltoni
Journal:  J Palliat Med       Date:  2008-04       Impact factor: 2.947

9.  Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio; Fabio Fulfaro
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

10.  Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Fabio Fulfaro; Federica Aielli; Lucilla Verna; Corrado Ficorella; Alessandra Casuccio; Salvatore Riina; Giuseppe Intravaia; Salvatore Mangione
Journal:  J Pain Symptom Manage       Date:  2007-07-16       Impact factor: 3.612

View more
  1 in total

1.  Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.

Authors:  Md Tariqul Haque Tuhin; Dengpan Liang; Fang Liu; Hala Aldawod; Toufiq Ul Amin; Joshua S Ho; Rasha Emara; Arjun D Patel; Melanie A Felmlee; Miki S Park; James A Uchizono; Mamoun M Alhamadsheh
Journal:  Nat Commun       Date:  2022-06-23       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.